10-QPeriod: Q2 FY2025

AMGEN INC Quarterly Report for Q2 Ended Jun 30, 2025

Filed August 6, 2025For Securities:AMGN

Summary

Amgen Inc. reported robust top-line growth for the second quarter and first half of 2025, with total revenues increasing by 9% and 10% respectively compared to the prior year periods. This growth was primarily driven by strong volume increases across key products, notably Repatha, EVENITY, BLINCYTO, and TEZSPIRE, which collectively offset modest net selling price declines. The company demonstrated significant profitability improvements, with net income soaring by 92% and 92% for the respective periods, and diluted EPS more than doubling year-over-year. This performance was supported by improved cost of sales as a percentage of revenue and well-managed selling, general, and administrative expenses, although R&D investments saw an increase. Despite the strong operational performance, investors should note the ongoing legal challenges, particularly the significant tax dispute with the IRS concerning past tax years, which continues through the judicial process. The company also faces ongoing patent litigations related to its key products like Repatha and Prolia/XGEVA, with several new biosimilar infringement lawsuits filed. While Amgen has a strong liquidity position with substantial cash and cash equivalents, its balance sheet reflects a notable decrease in cash from the prior year-end, largely due to significant debt repayments and dividend distributions. The company reiterated its commitment to capital allocation through debt reduction, dividends, and stock repurchases.

Financial Highlights

52 data points
Beta

Revenue

$9.18B

67.2% Gross Margin

Net Income

$1.43B

15.6% Net Margin

EPS (Diluted)

$2.65

Total Assets

$87.90B

Cash & Equivalents

$8.03B

Free Cash Flow

$1.91B

Financial Statements
Beta
Revenue$9.18B
Cost of Revenue$3.01B
Gross Profit$6.17B
SG&A Expenses$1.69B
Operating Expenses$6.52B
Operating Income$2.66B
Interest Expense$694.00M
Net Income$1.43B
EPS (Basic)$2.66
EPS (Diluted)$2.65
Shares Outstanding (Basic)538.00M
Shares Outstanding (Diluted)541.00M

Key Highlights

  • 1Total revenues increased by 9% in Q2 2025 and 10% in H1 2025, driven by strong volume growth in key products like Repatha, EVENITY, BLINCYTO, and TEZSPIRE.
  • 2Net income more than doubled year-over-year, increasing by 92% in both Q2 and H1 2025, indicating significant profitability improvement.
  • 3Diluted Earnings Per Share (EPS) also more than doubled, rising by 92% for both periods, reflecting enhanced profitability.
  • 4Cost of Sales as a percentage of total revenues decreased, contributing to improved gross margins and operating income.
  • 5Amgen continues to invest in Research and Development, with R&D expenses increasing by 21% in Q2 and 16% in H1 2025, primarily for late-stage clinical programs.
  • 6The company faces significant ongoing legal and tax disputes, including a substantial IRS tax examination and multiple patent litigations, which could materially impact future financial results.
  • 7Cash and cash equivalents decreased from $11.97 billion at the end of 2024 to $8.03 billion at the end of Q2 2025, primarily due to debt repayments and dividend payments.

Frequently Asked Questions

The substantial increase in net income and EPS for both the three and six months ended June 30, 2025, was primarily driven by a strong increase in total revenues due to volume growth in key products, coupled with a more favorable cost of sales as a percentage of revenue. These factors collectively led to a significant increase in operating income, which flowed down to net income and EPS. Improved management of selling, general, and administrative expenses also contributed to the profitability gains.

Amgen is contesting IRS notices for tax years 2010-2012 and 2013-2015, which propose significant adjustments related to profit allocation between U.S. and Puerto Rico entities, potentially resulting in substantial additional federal tax liabilities. The trial for the consolidated cases concluded in January 2025, with post-trial briefs due in October 2025. A decision from the U.S. Tax Court is not expected earlier than the second half of 2026. The company also faces ongoing examinations for later tax years and believes its accrual for income tax liabilities is appropriate, but acknowledges the uncertainty and potential for material adverse impact.

Amgen is experiencing or anticipating biosimilar competition for several of its products. For Prolia and XGEVA, patents expired in early 2025 in the U.S., and biosimilar competition has launched, leading to expected sales erosion in the second half of 2025. The company is actively engaged in litigation to defend its patents against biosimilar developers for these and other products.

Amgen highlighted interim results from the Phase 3 DeLLphi-304 trial for IMDELLTRA/IMDYLLTRA in small cell lung cancer, showing a significant reduction in the risk of death. Additionally, the Phase 3 FORTITUDE-101 trial for bemarituzumab in gastric cancer met its primary endpoint of overall survival. The company also presented data for MariTide™ (maridebart cafraglutide) in obesity, showing substantial weight loss and cardiometabolic improvements. Marketing authorization for TEPEZZA was granted in Europe for thyroid eye disease.